Alterity Therapeutics Lim... (ATHE)
4.22
0.23 (5.76%)
At close: Feb 20, 2025, 3:59 PM
4.19
-0.71%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 3.96 |
| Market Cap | 46.82M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.99 |
| PE Ratio (ttm) | -0.6 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 4.21 |
| Volume | 51,037 |
| Avg. Volume (20D) | 495,876 |
| Open | 4.46 |
| Previous Close | 3.99 |
| Day's Range | 4.11 - 4.25 |
| 52-Week Range | 1.00 - 5.87 |
| Beta | undefined |
About ATHE
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company ...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 29, 2003
Employees 10
Stock Exchange NASDAQ
Ticker Symbol ATHE
Website https://alteritytherapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for ATHE stock is "Strong Buy." The 12-month stock price forecast is $8, which is an increase of 89.57% from the latest price.
Buy 50.00%
Hold 0.00%
Sell 0.00%
3 weeks ago
+57.04%
Alterity Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
2 months ago
+17.5%
Alterity Therapeutics shares are trading higher after the company announced its last patient for the ATH434-201 Phase 2 trial has completed the study with topline results expected in early 2025.
